Clinical trials: Migraine With or Without Aura, open to volunteers
Migraine, Migraine Disease
Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals
Caffeine extracted from green tea to abort acute attack of Migraine
- Conditions
- Migraine, Migraine Disease, Migraine Headache, Migraine Headache, With or Without Aura
- Trial name
- NCT07022496
- Testing
- Caffeine (200 mg), triptans, NSAID (Nonsteroidal anti-inflammatory drugs)
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
PFO - Patent Foramen Ovale, Migraine
A Comparison of Biodegradable and Metal Occluders in Patients With PFO and Migraine
Migraine is one of the most common chronic neurological disorders, posing a significant global public health concern. Patent Foramen Ovale (PFO) is the most common congenital heart anomaly in adults.
- Conditions
- PFO - Patent Foramen Ovale, Migraine, Migraine Headache, Migraine Headache, With or Without Aura
- Trial name
- BioMetal (NCT06203873)
- Testing
- Biodegradable occluder, Metal occluder
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Migraine, Migraine With or Without Aura
New Methods for Evaluating Preventive Migraine Treatment
The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided.
- Conditions
- Migraine, Migraine With or Without Aura, Headache Disorders, Chronic Migraine, Headache
- Trial name
- NCT07071506
- Testing
- Active drug for chronic migraine treatment.
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
- Trial name
- NCT04743141
- Testing
- Rimegepant (PF-07899801)
- Where
- 124 sites in United States, Poland and 1 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Cluster Headache - Episodic and Chronic, Migraine Headache
Yogabased Movements for Primary Headaches (Migraine and/or Cluster Headache) - YOURHEAD
Brief Summary: Migraine and/or Cluster Headache: Study Overview Background: Migraine and cluster headache are two primary headache disorders that significantly impact quality of life and functionality in those affected.
- Conditions
- Cluster Headache - Episodic and Chronic, Migraine Headache, Migraine Headache, With or Without Aura, Migraine in Adults
- Trial name
- NCT07348783
- Testing
- Intervention yoga based exercises
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Karolinska Institutet
Migraine
Study of EVO756 in Adults With Migraine
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
- Trial name
- NCT07616128
- Testing
- EVO756, Dose 1, EVO756, Dose 2
- Where
- 45 sites in United States, Australia and 2 more
- Volunteers
- 330 people
- Sponsor
- Evommune, Inc.
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie
Migraine
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- UBRO PEDS OLE (NCT05127954)
- Testing
- Ubrogepant
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 1,200 people
- Sponsor
- AbbVie
Migraine With or Without Aura
A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea
The purpose of this study is to evaluate safety and effectiveness of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic…
- Trial name
- Rimegepant PMS (NCT07497854)
- Testing
- Rimegepant sulfate
- Volunteers
- 3,000 people
- Sponsor
- Pfizer
Migraine, Migraine Disease
A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with…
- Conditions
- Migraine, Migraine Disease, Migraine in Adults, Migraine Headache
- Trial name
- NCT07667621
- Testing
- Rimegepant, Zavegepant
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Migraine, With or Without Aura
Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults
The purpose of this study is to evaluate the long-term safety of BR005-036C tablets in the acute treatment of migraines
- Trial name
- NCT07835152
- Testing
- BR005-036C
- Where
- 81 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Brise Pharmaceuticals Co., Ltd.
Migraine, With or Without Aura
Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults
The purpose of this study is to compare the efficacy and safety of BR005-036C versus placebo in subjects with Acute Migraines
- Trial name
- NCT07792681
- Testing
- BR005-036C
- Where
- 83 sites in China
- Volunteers
- 2,079 people
- Sponsor
- Brise Pharmaceuticals Co., Ltd.